Pathological Complete Response and Prognosis in Patients Receiving Neoadjuvant Paclitaxel and Trastuzumab with and without Anthracyclines for Stage II and III, HER2-positive Operable Breast Cancer: A Single-institute Experience

Trastuzumab and various chemotherapy combinations have shown superior results in patients with primary and metastatic breast cancer. However, cardiotoxicity becomes a major adverse event when trastuzumab is used with anthracycline-containing regimens. The purpose of this study was to determine the c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2011-09, Vol.31 (9), p.3041-3046
Hauptverfasser:	HORIGUCHI, Jun, OYAMA, Tetsunari, TAKEYOSHI, Izumi, TAKATA, Daisuke, ROKUTANDA, Nana, NAGAOKA, Rin, ODAWARA, Hiroki, TOKINIWA, Hideaki, TOZUKA, Katsunori, KIKUCHI, Mami, SATO, Ayako
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Chemotherapy, Adjuvant Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Paclitaxel - administration & dosage Prognosis Receptor, ErbB-2 - metabolism Remission Induction Trastuzumab Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!